High-Flow Tracheal Therapy on Tracheobronchial Secretions in Tracheostomized Patients
Launched by CLINIQUES UNIVERSITAIRES SAINT-LUC- UNIVERSITÉ CATHOLIQUE DE LOUVAIN · Mar 20, 2025
Trial Information
Current as of April 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how high-flow tracheal therapy (HFT) affects the mucus and secretions in patients who have a tracheostomy, which is a procedure that creates an opening in the neck to help with breathing. The main goal is to see if using HFT changes the thickness and stickiness of these secretions compared to when HFT is not used. Additionally, the study will explore how HFT affects patients' breathing comfort and the appearance of their secretions. It will take place at Cliniques Universitaires Saint-Luc and is designed for adult patients who already use HFT at night and need regular suctioning of their trachea.
To participate in this study, individuals must be at least 18 years old and have a tracheostomy. However, those with insufficient secretions for testing or who have cognitive issues will not be eligible. Participants can expect to be part of a randomized crossover study, which means they may experience both the HFT and the standard care during the trial. This research aims to improve the management of secretions in tracheostomized patients and enhance their overall comfort.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (≥18 years old)
- • Tracheostomized patients
- • Patients requiring routine tracheal suctioning and already using HFT overnight
- Exclusion Criteria:
- • Insufficient secretions for analysis
- • Cognitive impairment or confusion
About Cliniques Universitaires Saint Luc Université Catholique De Louvain
Cliniques Universitaires Saint-Luc, affiliated with the Université Catholique de Louvain, is a leading academic medical center in Belgium dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, it focuses on a wide range of therapeutic areas, prioritizing patient safety and ethical standards. The institution is committed to fostering collaboration between researchers and clinicians to enhance medical knowledge and improve treatment outcomes, contributing significantly to the global scientific community and the advancement of evidence-based medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussels, , Belgium
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported